Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Aprotinin Inhibits SARS-CoV-2 Replication
Denisa Bojková, Marco Bechtel, Katie-May McLaughlin, et al.
Cells (2020) Vol. 9, Iss. 11, pp. 2377-2377
Open Access | Times Cited: 82

Showing 1-25 of 82 citing articles:

TMPRSS2 expression dictates the entry route used by SARS‐CoV‐2 to infect host cells
Jana Koch, Zina M. Uckeley, Patricio Doldan, et al.
The EMBO Journal (2021) Vol. 40, Iss. 16
Open Access | Times Cited: 288
Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates
Denisa Bojková, Marek Widera, Sandra Ciesek, et al.
Cell Research (2022) Vol. 32, Iss. 3, pp. 319-321
Open Access | Times Cited: 118
Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates
Liliana Rodrigues, Renata Bento Cunha, Tatiana Vassilevskaia, et al.
Molecules (2022) Vol. 27, Iss. 9, pp. 2723-2723
Open Access | Times Cited: 64
SARS-CoV-2 Antiviral Therapy
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Clinical Microbiology Reviews (2021) Vol. 34, Iss. 4
Open Access | Times Cited: 57
The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment
Lukas Wettstein, Frank Kirchhoff, Jan Münch
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1351-1351
Open Access | Times Cited: 56
Generation of a Sleeping Beauty Transposon-Based Cellular System for Rapid and Sensitive Screening for Compounds and Cellular Factors Limiting SARS-CoV-2 Replication
Marek Widera, Alexander Wilhelm, Tuna Toptan, et al.
Frontiers in Microbiology (2021) Vol. 12
Open Access | Times Cited: 41
Targeting the Pentose Phosphate Pathway for SARS-CoV-2 Therapy
Denisa Bojková, Rui Costa, Philipp Reus, et al.
Metabolites (2021) Vol. 11, Iss. 10, pp. 699-699
Open Access | Times Cited: 41
Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics
Yash Gupta, Oleksandr V. Savytskyi, Matt Coban, et al.
Molecular Aspects of Medicine (2022) Vol. 91, pp. 101151-101151
Open Access | Times Cited: 30
Aprotinin treatment against SARS‐CoV‐2: A randomized phase III study to evaluate the safety and efficacy of a pan‐protease inhibitor for moderate COVID‐19
Francisco Javier Redondo Calvo, Juan Fernando Padín, José Ramón Muñoz‐Rodríguez, et al.
European Journal of Clinical Investigation (2022) Vol. 52, Iss. 6
Open Access | Times Cited: 29
Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform
Denisa Bojková, Philipp Reus, Leona Panosch, et al.
iScience (2023) Vol. 26, Iss. 2, pp. 105944-105944
Open Access | Times Cited: 16
In Vitro Lung Models and Their Application to Study SARS-CoV-2 Pathogenesis and Disease
Natalie Heinen, Mara Klöhn, Eike Steinmann, et al.
Viruses (2021) Vol. 13, Iss. 5, pp. 792-792
Open Access | Times Cited: 37
Host directed therapies: COVID-19 and beyond
Devavrat Tripathi, Megha Sodani, Pramod Gupta, et al.
Current Research in Pharmacology and Drug Discovery (2021) Vol. 2, pp. 100058-100058
Open Access | Times Cited: 33
Trypstatin as a Novel TMPRSS2 Inhibitor with Broad-Spectrum Efficacy Against Corona and Influenza Viruses
Jan Lawrenz, Lukas Wettstein, Armando Rodríguez, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA Viruses
Quynh Xuan Thi Luong, Phuong Thi Hoang, Phuong T. Ho, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1481-1481
Open Access
From N-0385 to N-0920: Unveiling a Host-Directed Protease Inhibitor with Picomolar Antiviral Efficacy against Prevalent SARS-CoV-2 Variants
Gabriel Lemieux, Jimena Pérez‐Vargas, Antoine Désilets, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization
Veronica Di Sarno, Gianluigi Lauro, Simona Musella, et al.
European Journal of Medicinal Chemistry (2021) Vol. 226, pp. 113863-113863
Open Access | Times Cited: 30
Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises
Natesh Singh, Bruno O. Villoutreix
Computational and Structural Biotechnology Journal (2021) Vol. 19, pp. 2537-2548
Open Access | Times Cited: 28
Dysregulation of the kallikrein-kinin system in bronchoalveolar lavage fluid of patients with severe COVID-19
Caroline P. Martens, Pierre Van Mol, Joost Wauters, et al.
EBioMedicine (2022) Vol. 83, pp. 104195-104195
Open Access | Times Cited: 20
A Monoclonal Human Alveolar Epithelial Cell Line (“Arlo”) with Pronounced Barrier Function for Studying Drug Permeability and Viral Infections
Patrick Carius, Annemarie Jungmann, Marco Bechtel, et al.
Advanced Science (2023) Vol. 10, Iss. 8
Open Access | Times Cited: 12
Aprotinin—Drug against Respiratory Diseases
Alexandre V. Ivachtchenko, Andrey A. Ivashchenko, Dmitrii O. Shkil, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 11173-11173
Open Access | Times Cited: 11
Development of lung tissue models and their applications
Nalinrat Petpiroon, Woranan Netkueakul, Kanokwan Sukrak, et al.
Life Sciences (2023) Vol. 334, pp. 122208-122208
Closed Access | Times Cited: 11
Aprotinin (II): Inhalational Administration for the Treatment of COVID-19 and Other Viral Conditions
Juan Fernando Padín, José Manuel Pérez‐Ortiz, Francisco Javier Redondo Calvo
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7209-7209
Open Access | Times Cited: 4
Therapeutic approaches for SARS-CoV-2 infection
Ankur Gupta, Anish Pradhan, Vimal K. Maurya, et al.
Methods (2021) Vol. 195, pp. 29-43
Open Access | Times Cited: 24
Development and optimization of a high‐throughput screening assay for in vitro anti‐SARS‐CoV‐2 activity: Evaluation of 5676 Phase 1 Passed Structures
Winston Chiu, Lore Verschueren, Christel Van den Eynde, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 7, pp. 3101-3111
Open Access | Times Cited: 17
Antimicrobial peptides: A plausible approach for COVID-19 treatment
Pooja Rani, Bhupinder Kapoor, Monica Gulati, et al.
Expert Opinion on Drug Discovery (2022) Vol. 17, Iss. 5, pp. 473-487
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top